Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

1 Jun 2023

Abstract excerpt

Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp adenovirus (ChAdOx1) vaccine boost that elicits potent CD8 T cells and tumor regression. ChAdOx1 administered intravenously (i.v.) had 4-fold higher antigen-specific CD8 T cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37279110
DOI: 10.1016/j.celrep.2023.112599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regressionPMID 37279110Read ↗

Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T CellsSemantic proximity Read ↗

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read ↗

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity Read ↗

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.Semantic proximity Read ↗

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancerSemantic proximity Read ↗

Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and MetastasisSemantic proximity Read ↗

Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathwaySemantic proximity Read ↗

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read ↗

Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomasSemantic proximity Read ↗

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Cross-competition shapes CD8+ T cell hierarchies and fate after cancer neoantigen RNA vaccinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.